Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 10/20 | 1.00 |
| ▸ | DRD2 | P14416 | 6/20 | 1.00 |
| ▸ | DRD4 | P21917 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD5 | P21918 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxanthrine SCHEMBL13963768 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL29380697 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL13963759 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL13974053 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL4507980 | 0.99 | DRD1 (0.97) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL3879181 | 0.99 | DRD1 (0.97) | DRD1DRD2DRD4ADRA2AADRA2B | |
| Doxanthrine SCHEMBL3882738 | 0.99 | DRD1 (0.97) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL13963755 | 0.83 | DRD1 (0.71) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL13974052 | 0.83 | DRD1 (0.71) | DRD1DRD2DRD4ADRA2AADRA2B | |
| SCHEMBL3952852 | 0.83 | DRD1 (0.71) | DRD1DRD2DRD4ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | claimed |
| US-20160279146-A1 | METHODS AND PHARMACEUTICAL FORMULATIONS FOR TREATMENT OF SELECTIVE ESTROGEN-RECEPTOR MODULATOR-INDUCED ADVERSE DRUG REACTIONS | LIMOXIFEN B.V. (NL) | 2016-09-29 | — | — | US | disclosed |
| EP-2364317-B1 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | EFFIPHARMA INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318938-B2 | Trans-fused chromenoisoquinolines synthesis and methods for use | PURDUE RESEARCH FOUNDATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110190332-A1 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | EFFIPHARMA (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190332-A1 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | EFFIPHARMA (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010017093-A2 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | EFFIPHARMA, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2007098462-A2 | TRANS-FUSED CHROMENOISOQUINOLINES, SYNTHESIS AND METHODS FOR USE | PURDUE RESEARCH FOUNDATION (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030025-A1 | TRANS-FUSED CHROMENOISOQUINOLINES SYNTHESIS AND METHODS FOR USE | SLC6A3, HTR3B, SLC18A2 | DRD1 23/4885DRD2 4/4885DRD4 13/4885 |
| US-20110190332-A1 | DOPAMINE RECEPTOR LIGANDS WITH ENHANCED DURATION OF ACTION | PRLHR, OPRD1, SLC6A3 | DRD1 12/4885DRD2 4/4885DRD4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.